Nutritional intake and growth until two years of age in moderate and late preterms

BACKGROUND AND AIM

Moderate and late preterm infants (MLPTI) (gestational age 32 0/7-36 6/7 weeks), are at risk for suboptimal growth. This study evaluated adherence to nutritional recommendations until 6 months corrected age (CA), growth until 2 years CA, and associations between nutritional intake and growth until 2 years CA.

METHODS

We prospectively collected nutritional intakes from 100 MLPTI during the first week of life and at 6 weeks, 3 months, and 6 months CA. Anthropometry was assessed at birth, discharge, term age, and at 6 weeks, 3 months, 6 months, 1 year, and 2 years CA.

RESULTS

On day 7, <40% reached nutritional recommendations. Thereafter, >80% reached protein recommendations until 6 months of life, but <60% reached energy recommendations. Weight z-scores increased from -0.44 at term-age to 0.59 at 3 months CA, but declined to -0.53 at 2 years CA on the TNO curves. No significant associations were found between nutritional intake and growth until 2 years CA.

CONCLUSION

No associations were demonstrated between nutritional intakes and growth until 2 years CA, despite not reaching recommended intakes. Despite high efforts to optimize growth, MLPTI find their own growth curve in the first 2 years of life.

IMPACT

This research is pioneering in identifying how nutrition influences growth in moderate and late preterm infants (MLPTI) up to 2 years corrected age (CA). MLPTI often do not meet the recommended protein and energy intake in their first week of life, suggesting that current guidelines might be too high. No association was demonstrated between nutritional intake and growth of MLPTI in the first 2 years of life. Initially, MLPTI show an increase in weight z-scores from term age up to 3 months CA but experience a decline in weight z-scores at 2 years CA, according to TNO growth charts.

The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy

The interleukin-1 (IL-1) family is one of the first described cytokine families and consists of eight cytokines (IL-1β, IL-1α, IL-18, IL-33, IL-36α, IL-36β, IL-36γ and IL-37) and three receptor antagonists (IL-1Ra, IL-36Ra and IL-38). The family members are known to play an essential role in inflammation. The importance of inflammation in cancer has been well established in the past decades. This review sets out to give an overview of the role of each IL-1 family member in cancer pathogenesis and show their potential as potential anticancer drug candidates. First, the molecular structure is described. Next, both the pro- and anti-tumoral properties are highlighted. Additionally, a critical interpretation of current literature is given. To conclude, the IL-1 family is a toolbox with a collection of powerful tools that can be considered as potential drugs or drug targets.

Multi-centre study found that strict adherence to guidelines led to computed tomography scans being overused in children with minor head injuries

AIM

Our primary aim was to calculate the head computed tomography (CT) scan rate in children with a minor head injury (MHI) when the Dutch National guidelines were followed in clinical practice. The secondary aim was to determine the incidence of CT abnormalities and the guideline predictors associated with traumatic abnormalities.

METHODS

We performed a multi-centre, prospective observational cross-sectional study in the emergency departments of six hospitals in The Netherlands between 1 April 2015 and 31 December 2016.

RESULTS

Data on 1002 patients were studied and 69% of cases complied with the guidelines. The overall CT rate was 44% and the incidence of traumatic abnormal CT findings was 13%. CT scans were performed in 19% of children under two years of age, 48% of children between two and five years and 63% of children aged six years or more. Multivariate regression analysis for all age categories showed that CT abnormalities were predicted by a Glasgow Coma Scale of less than 15, suspicion of a basal skull fracture, vomiting and scalp haematomas or external lesions of the skull.

CONCLUSION

Strict adherence to the Dutch national guidelines resulted in CT overuse. New guidelines are needed to safely reduce CT scan indications.

Antioxidant properties of phytoestrogens

The oxidation of lipids is an autocatalytic process consisting of a number of well-defined interrelated chemical reactions. Its importance has long been recognized in the food and polymer industry, and recent advances in the understanding of vascular diseases have shown that lipid peroxidation also contributes to human disease. The various chemical stages of the reaction offer several therapeutic targets for inhibition, and from the structural characteristics of phytoestrogens it is anticipated that they should exhibit antioxidant properties. Alone, it is not sufficient for compounds such as the phytoestrogens to exhibit biological activity as antioxidants; the criteria that should be satisfied for this mechanism to be relevant biologically are discussed.

[Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]

OBJECTIVE

To investigate whether all preterm infants born before 33 weeks of gestation need cardiorespiratory monitoring due to the risk of cardiorespiratory disturbances following their first vaccination at 2 months of age.

DESIGN

A prospective observational cohort study.

METHOD

During a period lasting a little over a year, all preterm infants who were being cared for at the neonatal ward of Medical Centre Alkmaar because they had been born before 33 weeks of gestation received their first immunization at the age of 2 months and were subsequently monitored. Infants who had already been discharged by that time were readmitted for this purpose.

RESULTS

In this cohort of 41 premature infants whose mean gestational age was 30.8 weeks (SD: 1.9), 10 of these had a mild decrease in oxygen saturation or bradycardia; three developed a moderate cardiorespiratory event requiring tactile stimulation. The incidence of disturbances was higher in younger and lower-weight infants and those who had experienced more severe morbidity during the neonatal phase. Moderate disturbances only occurred in the infants who had not yet been discharged from hospital after birth.

CONCLUSION

It is recommended that still-hospitalized premature infants receive their first immunizations under cardiorespiratory monitoring, as events were observed during a period of 0-24 hours thereafter. In premature infants who had already been discharged - mainly because they were less premature or dysmature - immunization without cardiorespiratory monitoring appeared to be safe. Further research is needed for substantiating this strategy.

[Thrombocytopenia in two newborn babies. Unexpected serious complications in full-term babies]

Thrombocytopenia usually has a moderate course in full-term babies. Here, however, we describe two newborns with serious complications due to neonatal alloimmune thrombocytopenia. One patient was transferred to the paediatrician because of pallor, a swelling on the head and petechiae. He had a subgaleal hemorrhage. Following a platelet transfusion he made a complete recovery. The other presented with thrombocytopenia and petechiae and was treated with intravenous immunoglobulin. Several days later the patient started vomiting. Cranial ultrasound showed hydrocephalus most probably arising from an intraventricular haemorrhage following the thrombocytopenia, for which he received a ventriculoperitoneal drain. After this he made a successful recovery. Although neonatal alloimmune thrombocytopenia is a rare condition it can have serious consequences for the newborn and for subsequent pregnancies. It is important that treatment be started early and that cranial ultrasound always be performed.

Screening rules for growth to detect celiac disease: a case-control simulation study

Background

It is generally assumed that most patients with celiac disease (CD) have a slowed growth in terms of length (or height) and weight. However, the effectiveness of slowed growth as a tool for identifying children with CD is unknown. Our aim is to study the diagnostic efficiency of several growth criteria used to detect CD children.

Methods

A case-control simulation study was carried out. Longitudinal length and weight measurements from birth to 2.5 years of age were used from three groups of CD patients (n = 134) (one group diagnosed by screening, two groups with clinical manifestations), and a reference group obtained from the Social Medical Survey of Children Attending Child Health Clinics (SMOCC) cohort (n = 2,151) in The Netherlands. The main outcome measures were sensitivity, specificity and positive predictive value (PPV) for each criterion.

Results

Body mass index (BMI) performed best for the groups with clinical manifestations. Thirty percent of the CD children with clinical manifestations and two percent of the reference children had a BMI Standard Deviation Score (SDS) less than -1.5 and a decrease in BMI SDS of at least -2.5 (PPV = 0.85%). The growth criteria did not discriminate between the screened CD group and the reference group.

Conclusion

For the CD children with clinical manifestations, the most sensitive growth parameter is a decrease in BMI SDS. BMI is a better predictor than weight, and much better than length or height. Toddlers with CD detected by screening grow normally at this stage of the disease.

[Tick-borne disease or not? Do not let yourself be fooled]

Confusion among physicians and patients is increasing regarding the diagnosis and treatment ofLyme borreliosis due to the enormous amount ofambiguous information available and media attention. Some of the dilemmas that physicians encounter are illustrated by 3 patients with a range of symptoms, one of whom was convinced she had Lyme borreliosis. However none of these patients had significant evidence that suggested Lyme borreliosis. Physicians should follow the guidelines developed by the Dutch Institute for Health Care Improvement (CBO) or the Infectious Diseases Society of America rather than 'alternative' guidelines, which are not evidence-based.

[Two children seriously weakened by myasthenia]

Two boys, aged 2 and 11 years, presented with fever and muscle weakness that resulted in respiratory insufficiency. A physical examination and additional tests confirmed the diagnosis 'myasthenia'. Acetyl cholinesterase-inhibitor therapy had a favourable effect. Myasthenia is a diagnosis that should be considered for every child presenting with muscle weakness of unknown origin.

Catch-up growth and endocrine changes in childhood celiac disease. Endocrine changes during catch-up growth

Childhood celiac disease may lead to a failure of statural growth. After institution of a gluten-free diet most patients exhibit catch-up growth. Catch-up growth is a remarkable phenomenon characterized by a supranormal height velocity. One of the hypothetical mechanisms of catch-up growth is that an increased activity of the somatotrophic axis is involved. In order to provide further insight in the physiology of catch-up growth, auxological and endocrine changes were prospectively studied in 28 children with newly diagnosed celiac disease. The results demonstrate a malnutrition-like state of the somatotrophic axis at the time of diagnosis and a rapid recovery of this axis towards normal functioning after institution of the gluten-free diet. Although several correlations between these endocrine alterations and auxological parameters were detected, it is questionable whether the endocrine changes are the driving force behind catch-up growth.

Catch-up growth: definition, mechanisms, and models

Catch-up growth is characterized by height velocity above the limits of normal for age for at least 1 year after a transient period of growth inhibition; it can be complete or incomplete. Although catch-up growth can be expressed in terms of height velocity, the change in height standard deviation score is more appropriate. Catch-up growth is difficult to distinguish from the pubertal growth spurt. The increased growth rate following intrauterine growth retardation is usually called catch-up growth, although it does not meet all the criteria. It is not possible to know whether catch-up growth is complete for an individual child, but if final height is within the target range, it can be considered that catch-up growth has probably been complete. In groups of patients, complete catch-up growth is expected to result in a mean final height close to the mean target height. Increased growth velocity due to growth hormone (GH) therapy is accurately called catch-up growth in children with GH deficiency but should be called growth enhancement in children with other disorders. Two hypotheses have been proposed to explain the mechanism of catch-up growth: the neuroendocrine hypothesis, for which no persuasive experimental data have been produced, and the growth plate hypothesis, which cannot explain the increased growth rate observed in human catch-up growth.

L-arginine chlorination products inhibit endothelial nitric oxide production

The myeloperoxidase-derived oxidant hypochlorous acid (HOCl) is thought to contribute to endothelial dysfunction, but the mechanisms underlying this inhibitory effect are unknown. The present study tested the hypothesis that HOCl and L-arginine (L-Arg) react to form novel compounds that adversely affect endothelial function by inhibiting nitric oxide (NO) formation. Using spectrophotometric techniques, we found that HOCl and L-Arg react rapidly (k = 7.1 x 10(5) m(-1) s(-1)) to form two major products that were identified by mass spectrometry as monochlorinated and dichlorinated adducts of L-Arg. Pretreatment of bovine aortic endothelial cells with the chlorinated L-Arg metabolites (Cl-l-Arg) inhibited the -induced formation of the NO metabolites nitrate (NO(3)(-)) and nitrite (NO(2)(-)) in a concentration-dependent manner. Preincubation of rat aortic ring segments with Cl-L-Arg resulted in concentration-dependent inhibition of acetylcholine-induced relaxation. In contrast, blood vessels relaxed normally to the endothelium-independent vasodilator sodium nitroprusside. In vivo administration of Cl-L-Arg to anesthetized rats increased carotid artery vascular resistance. A greater than 10-fold excess of L-Arg was required to reverse the inhibitory effects of Cl-L-Arg in vivo and in vitro. Reaction of HOCl with D-arginine (D-Arg) did not result in the formation of inhibitory products. These results suggest that HOCl reacts with L-Arg to form chlorinated products that act as nitric-oxide synthase inhibitors.

Isoflavonoids and chronic disease: mechanisms of action

Soy and its isoflavones are associated with a reduced risk of chronic disease. The mechanisms of action of isoflavones include their roles as weak estrogens, inhibitors of tyrosine kinase-dependent signal transduction processes and as cellular antioxidants. Although estrogen receptor beta binds genistein with an affinity close to that of 17beta-estradiol, it remains to be determined whether it is a mediator of genistein's activity in vivo. Genistein's inhibition of protein tyrosine kinases is not limited to direct effect on these kinases, but may result from alteration in kinase expression. Genistein is not a particularly good scavanger of cellular oxidants; however, it reacts vigorously with the prooxidant hypochlorous acid, produced by neutrophils as part of the inflammatory response. The chlorinated isoflavones may have altered biochemical and biological effects compared to their parent compounds and may provide increased protection against inflammatory disease.

Growth curves of Dutch children with Down's syndrome

Two thousand and forty-five observations on height and weight were collected from 295 healthy Dutch children with Down's syndrome. In a cross-sectional analysis, means and standard deviations were calculated per age-class, and subsequently smoothed, resulting in age references between 0 and 20 years. Each child contributed only once in every age class. In a subgroup in whom more than four measurements were available before puberty, quadratic regression functions were determined on the basis of the full data set, as well as for individual children separately (54 boys and 25 girls). The average coefficients of the individual regression functions were almost identical to the coefficients of the regression line through all data, indicating that the reference curve for the mean height based on cross-sectional analysis adequately represents longitudinal growth during childhood. Dutch children with Down's syndrome are taller than their US peers (P50 equals P75) but more than 2 SD shorter than normal Dutch children. Above the age of 10 years, the mean weight for height is above the P90 of normal children.

Restricted catch-up growth after cessation of steroid treatment in a growth-hormone-deficient child

The phenomenon of catch-up growth has been known for a long time but its actual stimulus has remained unidentified. Involvement of growth hormone (GH) seems likely, but it is unknown whether normal GH secretion is an absolute prerequisite for catch-up growth. We present insight to this topic by describing a child with GH deficiency who showed a biphasic pattern of catch-up growth. During the first catch-up phase, she showed restricted catch-up growth in the absence of GH therapy, while she achieved nearly complete catch-up with GH therapy. Both periods of catch-up growth are compared separately with the response to GH therapy of age-matched, GH deficient patients with similar height deficit. This observation suggests that the first phase of catch-up growth in a child with severe growth retardation may be partially GH independent, while further catch-up requires normal GH levels.

Catch-up growth after prolonged hypothyroidism

This report presents an analysis of four patients who suffered from longstanding untreated hypothyroidism, with special attention to the phase of catch-up growth after the start of L-thyroxine treatment. Although a permanent height loss could not be prevented, the capacity to establish a remarkable catch-up growth spurt proved to be still intact, even after a long period of thyroid dysfunction.

CONCLUSION

Catch-up growth in hypothyroidism may be incomplete if treatment has been started shortly before or during puberty.

Fundamental voice frequency and jitter in girls and boys measured with electroglottography: influence of age and height

The fundamental frequency and jitter of the voice was measured by electroglottography in 71 children between the age of 7 and 15 years. In this series of children the fundamental frequency and jitter did not depend on the gender. The median (range) fundamental frequency was 244 (182-331) Hz in girls and 250 (205-293) Hz in boys. It decreased with increasing height (r = -0.59; P < 0.0005) and age (r = -0.57; P < 0.001). The median jitter ratio was 9.7 (1.6-33.3) in girls and 10.3 (2.0-4.3) in boys. The jitter ratio was negatively related to height (r = -0.31; P < 0.05), but not to age.

Catch-up growth in early treated patients with growth hormone deficiency. Dutch Growth Hormone Working Group

Catch-up growth of 26 children with growth hormone deficiency during four years of growth hormone treatment, which was started young (< 3 years), was compared with that of 16 children with coeliac disease on a gluten free diet. In children with growth hormone deficiency mean (SD) height SD score increased from -4.3 (1.8) to -1.9 (1.4) and in patients with coeliac disease from -1.8 (0.9) to -0.1 (0.8). Height SD score after four years correlated positively with injection frequency and height SD score at start of treatment in children with growth hormone deficiency. All patients with coeliac disease reached a height above -2 SD scores after four years, while the height of 26% of children with growth hormone deficiency on daily injections and of 86% of children on 2 or 4 injections/week was still below -2 SD scores. In patients with growth hormone deficiency on daily injections with an initial height SD score between -2 and -4 catch-up was similar to that of patients with coeliac disease with a comparable initial height deficit. Growth hormone deficient children with an initial height SD score < -4 did not reach full catch-up growth within four years. In conclusion, catch-up growth in early treated children with growth hormone deficiency over four years is adequate provided that daily injections are given and the initial height SD score is not less than -4.

Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group

BACKGROUND AND OBJECTIVE

Growth hormone treatment in children with idiopathic short stature (ISS) leads to growth acceleration in the first years, but the effect on final height is still poorly documented. We therefore studied the long-term effect of GH therapy in children with idiopathic short stature.

DESIGN

We have treated 27 prepubertal children with ISS with recombinant human GH (rhGH) in an initial dosage of 2 IU/m2 body surface/day subcutaneously, which was doubled either after the first year if the height velocity increment was less than 2 cm/year, or thereafter if height velocity fell below the P50 for bone age. Growth and bone maturation of the treatment group (ISS group, n = 21) were compared to those of an untreated control group with ISS (ISS controls, n = 27) and of a group of rhGH treated children with isolated GH deficiency (GHD group, n = 7).

RESULTS

In 9 patients of the ISS group still on treatment, height standard deviation score (HSDS) for chronological age increased from -3.8 +/- 0.7 to -2.3 +/- 0.9 (mean +/- standard deviation) over 6 years, while in matched ISS controls HSDS for age did not change. HSDS for age in the GHD group increased from -3.9 +/- 0.6 to -1.8 +/- 0.7 after 4 years, significantly more than the ISS group. Bone maturation was accelerated in the ISS and GHD groups. HSDS for bone age and predicted adult height did not change in either group. Final height in 12 children of the ISS group was -2.6 +/- 1.0 SDS. In the untreated controls final height was similar. A low integrated GH concentration over 24 hours, a low GH peak to provocative stimuli, and minimal initial BA delay predicted a favourable outcome.

CONCLUSION

rhGH treatment in this group of children with idiopathic short stature did not increase average final height. Part of the heterogeneity of the response can be attributed to the variation in endogenous GH secretion and initial bone age delay.

Catch-up growth in 60 children with celiac disease

The growth pattern of 28 girls and 32 boys with celiac disease was analyzed up to the ages of 10 and 12 years, respectively. Fifty-four patients (90%) were diagnosed before 4 years of age and six patients (10%) between 5 and 9 years of age. At diagnosis, 18 of 60 patients (30%) had a height SD score below -2.0, and 45 of 59 patients (76%) had a weight-for-height below the median. The mean height SD score showed increasing growth retardation in the year before diagnosis, relatively quick catch-up growth in the year after diagnosis, and complete catch-up in 2-3 years. Mean weight-for-height showed a progressive decrease 12-18 months before diagnosis, increased to a maximum at the end of the first year of therapy, and returned to normal 15 months after dietary treatment. Independent of age at diagnosis, initial degree of wasting, diagnostic delay, and strictness of gluten-free diet, catch-up growth was complete in this group of patients who were diagnosed before 9 years of age.

A mathematical model describing catch-up growth in celiac disease

Celiac disease may lead to various degrees of growth retardation. In general, catch-up growth is completed in the first 2 years after the start of therapy. A mathematical model for catch-up growth in celiac disease can be useful as a reference to which the growth pattern observed during treatment of other conditions can be compared. In this study we performed a non-linear regression analysis on individual growth data of 16 celiac disease patients using a monomolecular growth function. The goodness of fit was significant in all cases (p < 0.05), which illustrates that this function adequately describes catch-up growth in individuals with celiac disease. From the individual models we have composed a cross-sectional curve and a longitudinal description of the pattern of catch-up growth for the entire population.

The effect of oestrogen treatment on body proportions in constitutionally tall girls

Body proportions were studied in 31 girls with constitutional tall stature during treatment with 200 micrograms ethinyl oestradiol per day continuously, combined with 5-10 mg medroxyprogesterone on the first 10 days of each month. Their mean (+/- SD) predicted adult height was 186.0 (+/- 4.0) cm. At the start of therapy, leg length (LL) standard deviation score (SDS) (3.8 +/- 0.7) was significantly greater than the sitting height (SH) SDS (2.3 +/- 1.1). During therapy, the mean sitting height increased by 2.9 cm, in contrast to an increment of only 0.8 cm for LL. The SDS of the ratio between SH and LL remained below zero. The expected gain without therapy, assuming a stable SDS position over time, was 5.4 cm for SH and 4.4 cm for LL, significantly more than the observed gains. In conclusion, tall girls have relatively long legs. Oestrogen therapy leads to an almost complete stop of leg growth, while the growth of the trunk is reduced to a lesser extent. This selective inhibition results in a trunk/leg ratio which is closer to, though still significantly different from that of normal girls.